A new Italian study finds that estimated relative vaccine effectiveness (rVE) was 49.3% for the bivalent (two-strain) booster and 26.9% for the monovalent (single-strain) booster, with protection lasting at least 4 months for the bivalent booster and waning fast for the monovalent version. The study appears in The Lancet Infectious Diseases.
For the first time, researchers have calculated excess deaths among US dementia patients during the pandemic, and they found a reduction in excess mortality among long-term care residents after COVID-19 vaccines were made available. The study was published today in JAMA Neurology.
Recent Comments